ASP Isotopes Inc. has announced the overwhelming approval by Renergen Limited shareholders of the acquisition proposed by ASP Isotopes. The acquisition aims to create a global leader in the production of critical materials, including electronic gases such as helium, various fluorinated products, and isotopically enriched gases. The combination is expected to generate over $300 million in EBITDA in 2030.
The transaction is expected to be highly accretive to ASP Isotopes' revenue, EBITDA, earnings per share, and cash flow per share, starting from 2026. It is anticipated to create a vertically and horizontally integrated supply chain with substantial synergies from 2026.
Renergen, a public company focused on the production of liquefied helium (LHE) and liquefied natural gas (LNG), is funded by the United States government due to the strategic significance of helium. The combination of Renergen and ASP Isotopes is expected to have a profound impact on supply chain stability, particularly for the semiconductor and electronics industry, positioning the group well for the global AI revolution.
ASP Isotopes, a development stage advanced materials company, is dedicated to producing and commercializing highly enriched isotopes for the healthcare and technology industries. They also plan to enrich isotopes for the nuclear energy sector using quantum enrichment technology.
The press release did not provide specific metrics or numbers to indicate changes in various financial or operational metrics since the last period. The market has reacted to these announcements by moving the company's shares 1.07% to a price of $7.52. Check out the company's full 8-K submission here.
